Citations

Clear

1819 citation(s) found for "Israel, E".

Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study.
Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Meyer, Meghan E., Tamimi, Rulla M. , Borges, Virginia F. , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 515-515

10.1200/jco.2015.33.15_suppl.515 Get It

First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+ B-cell malignancies previously treated with anti-CD20 therapy.
Brownstein, Carrie , Adriaens, Lieve, Ansell, Stephen M. , Patel, Snehal G. , Kostić, Ana , Trail, Pamela A. , Lowy, Israel , Kohrt, Holbrook Edwin, Bannerji, Rajat , Chavez, Julio C , Levy, Ronald , Advani, Ranjana H.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS3089-TPS3089

10.1200/jco.2015.33.15_suppl.tps3089 Get It

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
Harshman, Lauren C. , Puligandla, Mäneka, Drake, Charles G. , McDermott, David F., Cella, David , Shuch, Brian , Lara, Primo, Kapoor, Anil , Heng, Daniel Yick Chin, Jewett, Michael A.S. , Master, Viraj A. , Leibovich, Bradley C. , Maskens, Deb, Investigators, On behalf of the PROSPER RCC, Haas, Naomi B , Allaf, Mohamad E , McDermott, David F. , Signoretti, Sabina , Gupta, Rajan T. , Choueiri, Toni K. , Michaelson, M. Dror , Carducci, Michael A. , Investigators, On behalf of the PROSPER RCC

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: TPS684-TPS684

10.1200/jco.2019.37.7_suppl.tps684 Get It

TPS684 Background: The anti-PD-1 antibody nivo improves overall survival in metastatic RCC and is well tolerated. There is no standard adjuvant systemic therapy that increases overall survival (OS) over surgery alone for non-metastatic RCC. Priming the immune system prior to surgery with anti-PD-1 has shown an OS benefit compared to a pure adjuvant approach in mouse solid tumor models. The PROSPER RCC trial aims to improve clinical outcomes by priming the immune system prior to nephrectomy with neoadjuvant nivo and continued engagement with adjuvant blockade in patients with high risk M0 RCC compared to surgery alone. Methods: This global, unblinded, phase 3 National Clinical Trials Network study is currently accruing patients with clinical stage ≥T2 or node positive M0 RCC of any histology. Tumor biopsy prior to randomization is mandatory to ensure RCC and permits in depth correlative science. The investigational arm will receive two doses of nivo 240mg prior to surgery followed by adjuvant nivo for 9 months (q2 wks x 3 mo followed by 480mg q4 wks x 6 mo). The control arm will undergo standard nephrectomy followed by observation. Randomized patients are stratified by clinical T stage, node positivity, and histology. To enhance accrual and patient quality of life, key upcoming amendments are being instituted. These include biopsy only in the nivo arm, allowance of oligometastatic disease and bilateral renal masses that can be fully resected/ablated, and change of nivo dosing to q4 wks (1 neoadj; 9 adj). With accrual of 766 patients, there is 84.2% power to detect a 14.4% absolute benefit in recurrence-free survival (RFS) at 5 years assuming the ASSURE historical control of ~56% to 70% (HR = 0.70). The study is also powered to evaluate a significant increase in overall survival (HR 0.67). Safety, feasibility, and quality of life endpoints critical to adjuvant therapy considerations are incorporated. PROSPER RCC embeds a wealth of translational work aimed at investigating the impact of the baseline immune milieu, the changes induced by neoadjuvant anti-PD-1 priming, and how both correlate with clinical outcomes. Clinical trial information: NCT03055013.
The “Skinny” on Assessment and Utilization of Steatotic Liver Grafts: A Systematic Review
Croome, Kristopher P. , Lee, David D. , Taner, C. Burcin , Croome, Kris P , Lee, David D

Mayo Clinic

Liver Transplantation | February 28, 2019 | Volume: 25 | Issue: 3 | Pages: 488-499

10.1002/lt.25408 | PMID 30817859 Get It

The frequency at which steatotic deceased donor liver grafts are encountered will likely continue to increase. Utilization of liver grafts with moderate‐to‐severe steatosis for liver transplantation (LT) has been previously shown to be associated with increased rates of primary nonfunction and decreased recipient survival. In order to better inform clinical decision making and guide future research, critical evaluation of the literature on donor liver steatosis and posttransplantation outcome is needed. This literature review aims to provide the “skinny” on using deceased donor steatotic livers for LT.
Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning
Hippel, Christiana von , Rosenberg, Shoshana M. , Austin, S. Bryn , Sprunck‐Harrild, Kim , Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Borges, Virginia F. , Partridge, Ann H. , von Hippel, Christiana , Come, Steven , Partridge, Ann H , Borges, Virginia F

Mayo Clinic

Psycho-Oncology | February 28, 2019 | Volume: 28 | Issue: 5 | Pages: 1033-1040

10.1002/pon.5047 | PMID 30817075 Get It

AbstractObjectivesTo identify and characterize distinct trajectories of change in young women's sexual functioning over the first 5 years following breast cancer diagnosis.MethodsGroup‐based trajectory modeling was applied to the sexual functioning of 896 women diagnosed with stage I‐IV breast cancer at age 40 or younger. The Cancer Rehabilitation Evaluation System was used to evaluate women's symptoms of sexual dysfunction annually for 5 years.ResultsFive distinct trajectories of sexual functioning were identified: one asymptomatic, one minimally symptomatic, two moderately symptomatic, and one severely symptomatic trajectory. Twelve percent of women were asymptomatic throughout follow‐up. The plurality of women experienced stable mild symptoms (42%). Among those with moderate symptoms, some experienced improvement over time (22%) while others experienced deterioration (13%); 11% experienced stable severe symptoms that did not remit over time. Independent predictors of experiencing a symptomatic rather than asymptomatic trajectory (P < 0.05, two‐sided) included diagnosis with stage 2 versus 1 disease, ER positive disease treated with oophorectomy or ovarian suppression, being partnered, having anxiety, poorer body image, and greater musculoskeletal pain.ConclusionsWe identified distinct trajectories that describe the reported sexual symptoms in this cohort of young breast cancer survivors. The majority of women reported various degrees of sexual dysfunction that remained stable over the study period. There is, however, potential for improvement of moderate and severe symptoms of sexual dysfunction in early survivorship.
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors
Leaf, Rebecca Karp , Ferreri, Christopher, Rangachari, Deepa, Mier, James W., Witteles, Wesley, Ansstas, George , Zubiri, Leyre , Oo, Thein Hlaing , Iberri, David , Yarchoan, Mark , Salama, April K.S. , Johnson, Douglas B. , Leavitt, Andrew D. , Rahma, Osama E. , Reynolds, Kerry L. , Leaf, David E. , Anagnostou, Theodora , Oo, Thein H , Iberri, David , Leaf, David E , Zubiri, Leyre , Yarchoan, Mark , Rangachari, Deepa , Piotrowska, Zofia

Mayo Clinic

American Journal of Hematology | February 21, 2019 | Volume: 94 | Issue: 5 | Pages: 563-574

10.1002/ajh.25448 | PMID 30790338 Get It

AbstractImmune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolutionized the treatment of cancer; however, these drugs can also cause a unique spectrum of autoimmune toxicity. Autoimmune hemolytic anemia (AIHA) is a rare, but often severe, complication of ICPis. We identified 14 patients from nine institutions across the United States who developed ICPi‐AIHA. The median interval from ICPi initiation to development of AIHA was 55 days (interquartile range [IQR], 22‐110 days). Results from the direct antiglobulin test (DAT) were available for 13 of 14 patients: 8 patients (62%) had a positive DAT and 5 (38%) had a negative DAT. The median pretreatment and nadir hemoglobin concentrations were 11.8 g/dL (IQR, 10.2‐12.9 g/dL) and 6.3 g/dL (IQR, 6.1‐8.0 g/dL), respectively. Four patients (29%) had a preexisting lymphoproliferative disorder, and two (14%) had a positive DAT prior to initiation of ICPi therapy. All patients were treated with glucocorticoids, with three requiring additional immunosuppressive therapy. Complete and partial recoveries of hemoglobin were achieved in 12 (86%) and 2 (14%) patients, respectively. Seven patients (50%) were rechallenged with ICPis, and one (14%) developed recurrent AIHA. Clinical and laboratory features of ICPi‐AIHA were similar in DAT positive and negative patients. ICPi‐AIHA shares many clinical features with primary AIHA; however, a unique aspect of ICPi‐AIHA is a high incidence of DAT negativity. Glucocorticoids are an effective first‐line treatment in the majority of patients with ICPi‐AIHA, and most patients who are rechallenged with an ICPi do not appear to develop recurrence of AIHA.
Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food Among Individuals Without Diabetes
Mendes‐Soares, Helena , Raveh-Sadka, Tali, Azulay, Shahar, Edens, Kim, Ben‐Shlomo, Yatir , Ofek, Tal, Bachrach, Davidi, Stevens, Josh , Segal, Lihi, Kashyap, Purna , Nelson, Heidi , Colibaseanu, Dorin , Cohen, Yossi

Mayo Clinic

JAMA Network Open | February 8, 2019 | Volume: 2 | Issue: 2 | Pages: e188102

10.1001/jamanetworkopen.2018.8102 | PMID 30735238 Get It

Haptoglobin Phenotype Is Associated With High-Density Lipoprotein–Bound Hemoglobin Content and Coronary Endothelial Dysfunction in Patients With Mild Nonobstructive Coronary Artery Disease
Levy, Andrew P. , Levy, Nina S., Asleh, Ayat, Goldenstein, Hagit, Segol, Inbar, Gulati, Rajiv , Lerman, Lilach O. , Asleh, Rabea , Lerman, Amir

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | February 7, 2019 | Volume: 39 | Issue: 4 | Pages: 774-786

10.1161/atvbaha.118.312232 | PMID 30727751 Get It

Objective— Coronary endothelial dysfunction (ED) is an early stage of atherosclerosis and is associated with impaired high-density lipoprotein (HDL) function. A functional polymorphism at the haptoglobin (Hp) gene locus (rs72294371) has been associated with marked differences in HDL structure and function. We sought to determine whether Hp phenotype was associated with coronary ED and whether the amount of hemoglobin (Hb) tethered to HDL via Hp was Hp-type dependent and associated with ED. Approach and Results— Microvascular and epicardial coronary endothelial function was assessed in 338 individuals with nonobstructive coronary artery disease. Microvascular ED was defined as <50% change in coronary blood flow and epicardial ED as ≥20% decrease in coronary artery diameter after intracoronary acetylcholine infusion. The amount of Hb bound to HDL was measured by ELISA after HDL purification from plasma samples using immune-affinity chromatography. One hundred and seventy of the individuals in this study (50.3%) were diagnosed with microvascular ED, 143 (42.3%) with epicardial ED, and 67 (19.7%) had diabetes mellitus (DM). Hp phenotype was significantly associated with microvascular ( P =0.01) and epicardial ED ( P =0.04) among DM individuals. There was a significant and inverse correlation between the amount of HDL-bound Hb and change in coronary blood flow (r=−0.40; P <0.0001) and in coronary artery diameter (r=−0.44; P <0.0001) in response to acetylcholine infusion. Hb content of HDL was significantly increased in individuals with Hp 2-2 and DM. In a logistic regression model, Hp 2-2 phenotype was associated with microvascular ED (odds ratio, 1.9; P =0.03) and the amount of HDL-bound Hb was an independent predictor of both microvascular (odds ratio, 4.6 for each 1-SD increase; P <0.0001) and epicardial (odds ratio, 2.2; P <0.0001) ED. Conclusions— Hp phenotype is significantly associated with coronary ED in DM individuals. This association is likely related to increased Hb tethering to HDL via Hp 2-2 in DM.
Association of Apolipoprotein E With Intracerebral Hemorrhage Risk by Race/Ethnicity
Marini, Sandro, Crawford, Katherine, Morotti, Andrea, Lee, Myung J., Pezzini, Alessandro, Moomaw, Charles J., Flaherty, Matthew L., Montaner, Joan, Roquer, Jaume, Jimenez-Conde, Jordi, Giralt-Steinhauer, Eva, Elosua, Roberto, Cuadrado-Godia, Elisa, Soriano-Tarraga, Carolina, Slowik, Agnieszka, Jagiella, Jeremiasz M., Pera, Joanna, Urbanik, Andrzej, Pichler, Alexander, Hansen, Björn M., McCauley, Jacob L., Tirschwell, David L., Selim, Magdy, Brown, Devin L., Silliman, Scott L., Worrall, Bradford B., Meschia, James F., Kidwell, Chelsea S., Testai, Fernando D., Kittner, Steven J., Schmidt, Helena, Enzinger, Christian, Deary, Ian J., Rannikmae, Kristiina, Samarasekera, Neshika, Salman, Rustam Al-Shahi, Sudlow, Catherine L., Klijn, Catharina J. M., Nieuwenhuizen, Koen M. van, Fernandez-Cadenas, Israel, Delgado, Pilar, Norrving, Bo, Lindgren, Arne, Goldstein, Joshua N., Viswanathan, Anand, Greenberg, Steven M., Falcone, Guido J., Biffi, Alessandro, Langefeld, Carl D., Woo, Daniel, Rosand, Jonathan, Anderson, Christopher D., Hardy, John , Benjamin, Emelia J. , Montaner, Joan , Rotter, Jerome I. , Seshadri, Sudha , Anderson, Christopher D. , Lubitz, Steven A. , Sudlow, Cathie , Rannikmäe, Kristiina , James, Michael L. , Testai, Fernando D. , Maguire, Jane , Brown, Devin L. , Tirschwell, David , Hansen, Björn M. , Elosúa, Roberto , Cuadrado‐Godia, Elisa , Soriano‐Tárraga, Carolina , Nieuwenhuizen, Koen M. van , Klijn, Catharina J.M. , Samarasekera, Neshika , Salman, Rustam Al‐Shahi , Pezzini, Alessandro , Delgado, Pilar , Lee, Chaeyoung , McCauley, Jacob L. , Marini, Sandro , Chen, Christopher , Bersano, Anna , van Nieuwenhuizen, Koen M , Seshadri, Sudha , Hardy, John , Montaner, Joan , Benjamin, Emelia J , Lubitz, Steven A , Rotter, Jerome I , Pezzini, Alessandro , Crawford, Katherine, Morotti, Andrea, Lee, Myung J., Moomaw, Charles J., Flaherty, Matthew L., Roquer, Jaume, Jimenez-Conde, Jordi, Giralt-Steinhauer, Eva, Slowik, Agnieszka, Jagiella, Jeremiasz M., Pera, Joanna, Urbanik, Andrzej, Pichler, Alexander, Hansen, Björn M., Selim, Magdy, Brown, Devin L., Silliman, Scott L., Worrall, Bradford B., Meschia, James F., Kidwell, Chelsea S., Kittner, Steven J., Schmidt, Helena, Enzinger, Christian, Deary, Ian J., Salman, Rustam Al-Shahi, Fernandez-Cadenas, Israel, Delgado, Pilar, Norrving, Bo, Lindgren, Arne, Goldstein, Joshua N., Viswanathan, Anand, Greenberg, Steven M., Falcone, Guido J., Biffi, Alessandro, Langefeld, Carl D., Woo, Daniel, Rosand, Jonathan, Anderson, Christopher D., Al-Shahi Salman, Rustam , Bersano, Anna , Testai, Fernando D , McCauley, Jacob L

Mayo Clinic

JAMA Neurology | February 6, 2019 | Volume: 76 | Issue: 4 | Pages: 480

10.1001/jamaneurol.2018.4519 | PMID 30726504 Get It